Mativ Holdings reported disappointing quarterly results and missed revenue forecasts, prompting analysts to raise their price target to US$21.00 while keeping long-term estimates unchanged.
Mativ Holdings announced a quarterly dividend of $0.10 per share, yielding 3.42% forward. The payment is scheduled for December 18 to shareholders of record on November 27.
Mativ Holdings Inc. is scheduled to go ex-dividend on August 28, 2026, paying $0.10 per share. The company currently offers a dividend yield of 0.54% with an annualized payout of $0.40.
Mativ Holdings Inc. stock data indicates a closed market with no trades recorded. The content outlines available financial metrics and community features on the TradingView platform.
Mativ Holdings Inc. financial actuals and estimates are detailed, covering income statements, balance sheets, and analyst forecasts for the FWB:MH2 ticker.
Mativ Holdings Inc. presents financial actuals and estimates including stock price, market cap, and earnings. Analyst targets and upcoming earnings dates are highlighted for investor review.
Mativ Holdings Inc reports weak financial health in the Chemicals sector, ranking 58th out of 68 peers with a 97.20% drop in net profit and a 1.07% revenue decline to $479.60 million year-over-year.
Mativ Holdings Inc. submitted an amended Schedule 13G filing indicating changes in beneficial ownership, categorized under 'Others' distinct from institutional reports.
Mativ Holdings Inc. is gaining investor attention due to dividend stability and cash flow coverage, supporting long-term income sustainability alongside its specialty materials production for industri
Mativ Holdings approaches its ex-dividend date with a 4.6% yield, supported by sustainable payout ratios despite a 13% annual earnings decline over the past five years.
Mativ Holdings Inc. will go ex-dividend in four days with a US$0.10 per share payment, yielding 4.6%, despite a 13% annual earnings decline over the past five years.
Mativ Holdings reported Q1 2026 earnings with adjusted EBITDA up 28% year-over-year. Strategic pricing and debt refinancing drive margin expansion despite mixed healthcare demand.
Mativ Holdings reported improved Q1 adjusted EBITDA and cash flow driven by pricing and cost cuts, despite healthcare demand softness and raw material inflation. The company aims to maintain profitabi
Mativ Holdings Inc. reported Q1 2026 results with adjusted EBITDA margins expanding 220 basis points to 9.9% despite flat revenues of $479.6 million. Operational improvements drove profitability gains
Mativ Holdings declared a $0.10 quarterly dividend payable on June 19th, maintaining a 43% payout ratio. Analysts project $1.25 EPS next year, supporting the continuation of its $0.40 annual dividend.
Mativ Holdings reduced Q1 2026 GAAP losses by 97% to $11.7 million despite a 1.1% sales drop. Adjusted EBITDA increased 28% to $47.5 million, accompanied by a new quarterly cash dividend.
Mativ Holdings shareholders approved an expansion of the 2024 Equity and Incentive Plan, increasing the share pool by 1.6 million shares. Additionally, shareholders re-elected two directors and ratifi
Mativ Holdings missed Q1 2026 revenue and EPS estimates with a 1.1% revenue decline, though gross profit rose 16.9%. The company recorded a $11.7 million net loss amidst mixed institutional investor s
Mativ Holdings reported Q1 2026 sales of $479.6 million, down 1.1% year-over-year, while adjusted EBITDA rose 28% to $47.5 million alongside a quarterly dividend announcement.
Mativ Holdings reported a first-quarter net loss of $11.7 million with revenue reaching $479.6 million. Adjusted earnings stood at 6 cents per share, while the company recorded a 22-cent per share los
Mativ Holdings stock trades at $9.39, deemed 55% undervalued with 143% annual earnings growth projected, though dividend coverage remains weak.
Mativ Holdings' stock price target has been raised by 17.74% to $18.62, reflecting an updated outlook on the company's stock valuation.
Mativ Holdings reported a 22% drop in short interest in April, alongside quarterly EPS of $0.15 exceeding estimates and a new $0.10 dividend announcement.
Mativ Holdings Inc. is set to release Q1 2026 earnings on May 6th, forecasting $0.02 EPS and $486.9M revenue. This follows a prior quarter where the company exceeded EPS estimates despite reporting a
Mativ Holdings Inc. announced it will release Q1 2026 financial results after market close on May 6, 2026. A conference call to discuss these results is scheduled for May 7 at 8:30 a.m. ET.
Mativ Holdings is projected to achieve 146.9% annual earnings growth and 4% revenue growth, with analysts adjusting price targets amid upcoming dividend and share repurchase activities.
Mativ Holdings Inc. will release Q1 2026 financial results after market close on May 6, 2026, with an investor conference call scheduled for May 7.
Mativ Holdings Inc. surged 104.33% over the past year, outperforming the S&P 500 within the specialty chemicals sector. While showing growth potential, investors remain cautious regarding rising raw m
Mativ Holdings' market capitalization increased by US$53 million after an 11% stock gain, with President Shruti Singhal purchasing US$230k worth of shares.
Mativ Holdings reported a 21.3% increase in short interest to 1.41 million shares in March. Analysts maintain a 'Reduce' consensus despite Q4 EPS beats, citing negative net margins and P/E ratios.
Mativ Holdings secured approximately $894.9 million in new credit through a Ninth Amendment to its multicurrency agreement. The restructuring includes a $305 million revolving facility and establishes
Mativ Holdings Inc amended its multicurrency credit agreement on April 3, 2026. As a specialty materials manufacturer, the company also noted recent Q4 2025 earnings and dividend activities.
JPMorgan Chase led a $500 million leveraged loan sale for Mativ Holdings at a discount, signaling softening credit markets. Mativ faces challenges from high debt and weak industrial demand amidst broa
Mativ Holdings released its 2026 investor presentation, reporting a $2.0 billion trailing revenue run rate and $225 million adjusted EBITDA. The company emphasized strategic transformations and capita
ChemBrief